Sentinel lymph node biopsy in early breast cancer: Has its time come?

Journal of the National Cancer Institute

Volumn 98, Issue 9, 2006, Pages 568-569

  Pater, Joseph L ^a   Parulekar, Wendy ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPETENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY CANCER; EDITORIAL; EXPERIENCE; FALSE NEGATIVE RESULT; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; METHODOLOGY; MORBIDITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SAFETY; SENTINEL LYMPH NODE BIOPSY; SURGEON; TIME; TREATMENT OUTCOME; AXILLA; BREAST TUMOR; COLLOID; CONTROLLED CLINICAL TRIAL; FEMALE; LABORATORY DIAGNOSIS; LENGTH OF STAY; LYMPHADENECTOMY; MALE; MULTICENTER STUDY; NOTE; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; WOUND DRAINAGE;

CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT;

AXILLA; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COLLOIDS; CONTRAST MEDIA; DRAINAGE; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LENGTH OF STAY; LYMPH NODE EXCISION; MALE; MULTICENTER STUDIES; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 33646452281     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj183     Document Type: Editorial

References (15)

1. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst 2006;98:599-609.
2. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality of life assessment: Patient compliance with questionnaire completion. J Natl Cancer Inst 1992;84:1023-6.
3. Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 1998;17:667-77.
4. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-3.
5. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Can 2005;41:280-7.
6. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-20.
7. King TA, Fey JV, Van Zee KJ, Heerdt AS, Gemignani ML, Port ER, et al. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann Surg Oncol 2004;11:535-41.
8. Waddington WA, Keshtgar MR, Taylor I, Lakhani SR, Short MD, Ell PJ. Radiation safety of the sentinel lymph node technique in breast cancer. Eur J Nucl Med 2000;27:377-91.
9. Julian TB, Krag D, Brown A, Anderson S, Harlow S, Ashikaga T, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 2004 (suppl. 11, abstr. 14).
10. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.
11. Julian TB, Anderson S, Brown A, Krag D, Harlow S, Bear H, et al. Continued technical results of NSABP B-32: Does a positive sentinel node biopsy require an axillary dissection? Breast Cancer Res Treat 2005 (suppl. 1, abstr. 20).
12. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial. J Clin Oncol 2005;23:4312-21.
13. National Cancer Institute - Clinical Trials PDQ. Phase III randomized study of axillary lymph node dissection in women with stage I or IIA breast cancer who have a positive sentinel node. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 67018&version=healthprofessional.
14. National Cancer Institute - Clinical Trials PDQ. Phase III randomized study of complete Axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node-positive women with operable invasive breast cancer. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 68566&version=HealthProfessional&protocolsearchid=2189484
15. National Cancer Institute - Clinical Trials PDQ. Phase III randomized study of surgical resection with or without axillary lymph node dissection in women with clinically node-negative breast cancer with sentinel node micrometastases. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 339581&version=HealthProfessional&protocolsearchid=2189484